Blood Group Immunology

A red-cell antibody can reflect antigen exposure, lymphocyte activation, and class switching. Its structure and specificity help determine the temperature and reaction phase where it appears, the strength of the reaction, and the way an incompatible red cell is removed from circulation.

Immune response, antibody memory, and tolerance

Innate immunity provides the immediate cellular and soluble response. Phagocytes, natural killer cells, cytokines, and the alternative complement pathway recognize broad patterns and respond quickly. Adaptive immunity uses antigen-specific B and T lymphocytes. B cells bind antigen and, for T-dependent antigens, receive helper T-cell signals before differentiating into antibody-secreting plasma cells. Macrophages and dendritic cells process and present antigen. Antibody and complement opsonize targets for phagocytosis.¹

The first exposure to a red-cell alloantigen selects a small population of responsive lymphocytes. During a primary immune response, early plasma cells commonly produce IgM. Clinically significant red-cell alloantibodies may already be IgG when first detected. Germinal-center B cells can switch heavy-chain class while preserving antigen specificity, undergo affinity maturation, and form long-lived memory cells. Primary red-cell alloantibodies often require several weeks to reach a detectable level. A secondary, or anamnestic, response recruits memory cells and can become detectable within days to a few weeks. The antibody concentration may later fall below the method’s detection limit while memory cells persist.^1,2

This anamnestic response explains delayed hemolytic transfusion reactions. A patient with a historical antibody can have a negative current screen, receive antigen-positive cells, and develop a renewed antibody response while the transfused cells remain in circulation. The transfusion service retains clinically significant antibody histories and uses them to select antigen-negative red cells even when the current screen is negative.^1,2,3

Alloimmunization varies among recipients. Antigen dose and density, inflammation at the time of exposure, HLA-mediated antigen presentation, immune-response genes, pregnancy, transfusion history, and immunosuppression all change the probability of a response. Future responder status remains unknown before exposure because routine serology detects antibodies after they form.^1,2

Tolerance is antigen-specific unresponsiveness. Central and peripheral mechanisms normally limit responses to self antigens. Early exposure to genetically distinct red cells can produce lasting tolerance in a blood-group chimera and create an unusual typing pattern. A syngeneic donor and recipient, such as genetically identical twins, share the inherited antigens relevant to alloimmunization. Rh immune globulin is passive IgG anti-D used under a clinical protocol for an eligible, unsensitized D-negative patient. It binds D-positive fetal red cells and helps prevent maternal immune priming. Rh immune globulin prophylaxis applies before immune anti-D forms. Passive anti-D can make an antibody screen positive, so the laboratory uses dose, timing, and history when interpreting the result.¹

Immunoglobulin structure and class

An immunoglobulin monomer contains two identical heavy chains and two identical light chains joined by disulfide bonds. Variable regions at the amino-terminal ends form two antigen-binding sites. The remaining constant regions determine class and effector function. In IgG, papain cleavage produces two antigen-binding Fab fragments and one Fc fragment. The Fc region engages Fc receptors, can recruit C1q to begin classical complement activation, and enables IgG transport across the placenta.¹

The physical values are rounded teaching estimates; measured concentrations and half-lives vary among individuals and clinical settings.¹

IgG has four subclasses. IgG1 and IgG3 interact efficiently with Fc receptors and account for many clinically important red-cell antibodies. Both can activate classical complement, with IgG3 usually more effective; IgG2 activates weakly and IgG4 has little classical-pathway activity. Antibody concentration, subclass, specificity, antigen density, and Fc spacing together influence cell clearance. Clinical severity depends on all of these properties.^1,4

Immunoglobulins also carry three levels of antigenic variation. Isotypes are the classes and subclasses shared across the species. Allotypes are inherited constant-region variants found in some individuals. Idiotypes are the variable-region features that give an individual antibody its specificity.¹

Antigen-antibody binding and agglutination

An antibody binds an epitope through reversible hydrogen bonds, electrostatic attraction, van der Waals forces, and hydrophobic interactions. Affinity is the strength of one antigen-binding site for one epitope. Avidity is the combined strength of all bonds in a multivalent antigen-antibody complex. Specificity is the epitope or related group of epitopes that the antibody recognizes. Cross-reactivity is binding to different antigens that share a structure recognized by the same antibody.¹

Blood-bank antibodies can be classified along several independent axes:

Each pair classifies a different feature. Expected/unexpected identifies the testing context; alloantibody/autoantibody identifies the target; naturally occurring/immune identifies exposure history; polyclonal/monoclonal identifies reagent production.¹

Visible agglutination requires both sensitization and lattice formation. During sensitization, Fab binds antigen on the red-cell surface. Lattice formation follows when antibodies or antiglobulin reagent bridge neighboring cells into a visible aggregate. Soluble antigen-antibody complexes can form a precipitate. Complement-mediated hemolysis is a positive serologic reaction when the controls confirm that the test reaction caused it.^1,4

Reaction strength

The proportions of antigen and antibody affect lattice formation. Near equivalence, enough open binding sites remain on both reactants to build a large lattice. Prozone is antibody excess, which can coat available sites and leave too few bridges for a visible reaction. Postzone is antigen excess, which can occupy available antibody and produce small complexes. Diluting serum can resolve prozone; increasing the serum-to-cell ratio can resolve postzone.¹

Dosage occurs when an antibody reacts more strongly with cells carrying a double dose of the target allele than with heterozygous cells. Rh C, c, E, and e; MNS; Duffy; and Kidd antibodies often show this pattern. Excluding a dosage-sensitive specificity requires homozygous reagent cells.¹

Red cells carry a negative surface charge, produced largely by membrane sialic acid. Counter-ions in the surrounding fluid create an electrostatic barrier called zeta potential. Large, multivalent IgM can span the distance between cells and agglutinate them directly. Smaller IgG molecules usually sensitize cells without producing a visible saline lattice. LISS or PEG can increase IgG sensitization. After unbound protein is removed, antihuman globulin (AHG) reagent bridges IgG-sensitized cells into visible agglutinates.¹

Temperature, pH, ionic strength, incubation time, reactant concentration, centrifugation, antigen density, and reagent treatment all change reaction strength. Many red-cell antigen-antibody reactions are strongest near pH 6.5–7.5, with specificity-dependent exceptions. For a cool-reactive antibody, reactivity approaching 37 °C has greater clinical significance than reactivity confined to cold conditions.¹

Test conditions and detection methods

Tube methods separate immediate-spin, 37 °C, and AHG phases. Column-agglutination and solid-phase methods combine or replace some of these steps.¹

FDA-cleared antibody-detection products differ in specimen acceptability; some allow serum or plasma for the indirect antiglobulin test (IAT). Direct antiglobulin testing commonly uses EDTA-anticoagulated blood because EDTA limits complement attachment after collection. Each package insert lists the collection and storage limits for that product.^5,6,7

Enhancement media change the physical environment of sensitization.¹

AHG reagent detects the human globulins named on its label. Monospecific anti-IgG detects cell-bound IgG. The cited polyspecific AHG reagents contain anti-IgG plus anti-C3d. A direct antiglobulin test (DAT) on properly collected EDTA blood detects IgG and/or complement already bound to the patient’s red cells at collection. The IAT incubates patient serum or plasma with reagent or donor red cells to produce sensitization in the laboratory. Before detection, IAT methods remove unbound immunoglobulin by washing or column separation.^5,6

Chemical treatment separates IgM from IgG reactivity in mixed reactions. Dithiothreitol or 2-mercaptoethanol treatment of serum disrupts IgM pentamers and removes their reactivity while preserving most IgG reactivity. Dithiothreitol treatment of red cells also destroys Kell and several additional antigens. DTT-treated cells leave anti-K and antibodies to other DTT-sensitive antigens unresolved. ZZAP, a combination of dithiothreitol and a proteolytic enzyme, removes bound IgG from red cells and changes several red-cell antigens; it prepares sensitized cells for selected adsorption and serologic studies.^1,8

Flow cytometry measures fluorescent signals on individual cells. In transfusion medicine it can measure small populations of antigen-positive cells, low levels of cell-bound immunoglobulin, and relative antigen density.¹

Complement activation and hemolysis

Complement includes more than 30 soluble and membrane-associated proteins. Three initiation routes converge on C3 cleavage; the classical and alternative routes are most relevant to red-cell immunology. Antigen-bound IgM and sufficiently clustered IgG can initiate the classical pathway, while the alternative pathway can amplify complement already deposited on a susceptible surface. Calcium and magnesium support specific cascade steps; EDTA chelation blocks activation in a collected specimen.^1,4

The lectin route begins when pattern-recognition molecules bind microbial carbohydrates and forms the same C3 and C5 convertases as the classical route.¹

The classical and alternative pathways produce C3b, which covalently coats the target and acts as an opsonin. C3b also helps form a C5 convertase. C5 cleavage releases C5a, which promotes inflammation and chemotaxis, and starts assembly of C5b-9, the membrane attack complex. It forms a pore that can produce intravascular hemolysis. C3a also promotes inflammation. Factor H, factor I, C1 inhibitor, CD55, CD59, and other regulators limit host-cell injury.^1,4

Complement activation and hemolysis depend on antibody class and subclass, antigen density, Fc spacing, thermal range, and the target cell’s regulatory proteins. In an ABO-incompatible transfusion, IgM ABO antibodies can drive rapid terminal-pathway activation and intravascular hemolysis. Anti-P, anti-PP1P^k, anti-Vel, and some Kidd antibodies can also cause complement-mediated hemolysis. Rh, Kell, and Duffy antibodies more often coat red cells for extravascular removal by splenic or hepatic phagocytes. Cool-reactive Lewis, P1, and I antibodies may bind complement during testing while showing limited clinical effect when their thermal range stays far below 37 °C.^1,4

Polyspecific anti-IgG, anti-C3d AHG detects C3d that remains on a red cell after the initiating antibody has dissociated. This explains a DAT that reacts with anti-C3d while monospecific anti-IgG is nonreactive. The result establishes C3d coating within the reagent’s detection limit. Clinical history, hemolysis markers, antibody results, and specimen handling determine whether the coating accompanies active hemolysis.^4,5,6

Worked example: anti-Jk^a with a nonreactive screen

A patient previously formed anti-Jk^a, and the current antibody screen is nonreactive. The record still identifies a clinically significant alloantibody. The concentration of a Kidd antibody can fall below routine detection; Kidd antibodies also show dosage and often bind complement. Transfusion of Jk^a-positive red cells can recruit memory B cells and produce an anamnestic response followed by shortened donor-cell survival. The laboratory selects Jk^a-negative red-cell units, performs an antiglobulin crossmatch, and preserves the antibody history for future testing.^1,2,3,4

Interpretation combines antibody history, immunoglobulin class and thermal range, reaction phase and method, and evidence of Fc- or complement-mediated red-cell clearance.^1,4

References

1. Bloch EM, Campbell-Lee S, McKenna DH Jr, Montemayor-Garcia C, Schwartz J, Shaz B, Storry J, eds. Technical Manual. 22nd ed. AABB; 2026. Accessed August 27, 2026.
2. Hendrickson JE, Eisenbarth SC, Tormey CA. Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Curr Opin Hematol. 2016;23(6):543-549. doi:10.1097/MOH.0000000000000277.
3. AABB, American Red Cross, America's Blood Centers, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. June 2024. Accessed August 27, 2026.
4. Arthur CM, Chonat S, Fasano R, et al. Examining the role of complement in predicting, preventing, and treating hemolytic transfusion reactions. Transfus Med Rev. 2019;33(4):217-224. doi:10.1016/j.tmrv.2019.09.006.
5. Ortho-Clinical Diagnostics, Inc. MTS Anti-IgG, -C3d Card Instructions for Use. U.S. Food and Drug Administration. Accessed August 27, 2026.
6. Alba Bioscience Limited. Anti-Human Globulin Anti-IgG, -C3d; Polyspecific Package Insert. U.S. Food and Drug Administration. Accessed August 27, 2026.
7. Ortho-Clinical Diagnostics, Inc. 0.8% SELECTOGEN Reagent Red Blood Cells Instructions for Use. U.S. Food and Drug Administration. Accessed August 27, 2026.
8. Branch DR, Petz LD. A new reagent (ZZAP) having multiple applications in immunohematology. Am J Clin Pathol. 1982;78(2):161-167. doi:10.1093/ajcp/78.2.161.